China Pharma starts marketing pHGF
China Pharma Holdings says that it has started distribution of its hepatocyte growth-promoting Factor (pHGF) after receiving regulatory approval from China's State Food and Drug Agency.
pHGF is an extracted and purified peptide that promotes repair and growth in liver cells, which is indicated for the adjunct treatment of hepatitis at various stages. This product is manufactured at the company's Good Manufacturing Practice-standard facility in Haikou and it is currently available as an injectable form in 20mg per vial strength.
According to recent data from the World Health Organization, hepatitis B is a serious health problem in China with carrier rate of around 10%, among one of the highest in the world, said the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze